References
- Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93–101.
- [cited 2021 May 22]. Available from: https://www.wsj.com/articles/rare-black-fungus-mucormycosis-infects-thousands-of-covid-19-survivors-in-india-11621614697.
- Mahalaxmi I, Jayaramayya K, Venkatesan D, et al. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021;201:e111643.
- Waldorf AR, Diamond RD. Aspergillosis and mucormycosis. In: Immunology of the fungal diseases. Boca Raton: CRC Press; 2020. p. 29–55.
- Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009;15:2–9.
- [cited 2021 May 22]. Available from: https://www.bbc.com/future/article/20210519-mucormycosis-the-black-fungus-hitting-indias-covid-patients.
- Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421.
- Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐and Middle‐income countries. Mycoses. 2021;64(9):1028–1037.
- Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010;12(6):423–429.
- Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032–1037.
- Henry ME, Bolo NR, Zuo CS, et al. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother. 2013;57(11):5271–5276.
- Sundaram ASM, Sathanantham ST, Chinchole V, et al. Fostering a deeper understanding of COVID-19-associated mucormycosis–a commentary on the mucormycosis coinfection in the context of global COVID-19 outbreak: a fatal addition to the pandemic spectrum. Int J Surg. 2021;2021:e106031.
- Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–1360.
- Krishnan JKS, Arun P, Appu AP, et al. Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning. Neurotoxicology. 2016;53:64–73.
- Khafagy R, Gupta S, Campisi P, et al. Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology. Pediatr Blood Cancer. 2020;67(4):e28175.
- Tyagi AK, Malik A. Liquid and vapour-phase antifungal activities of selected essential oils against candida albicans: microscopic observations and chemical characterization of Cymbopogon citratus. BMC Complement Altern Med. 2010;10:65.
- Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules. 2009;14(9):3754–3779.
- Hoenigl M, Seidel D, Carvalho A, et al. The Emergence of COVID-19 Associated Mucormycosis: analysis of cases from 18 Countries. 2021; [cited 2021 Oct 30]. Available from: https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ppcovidwho-8778.
- Kalantar-Zadeh K, Ward SA, Kalantar-Zadeh K, et al. Considering the effects of microbiome and diet on SARS-CoV-2 infection: nanotechnology roles. ACS Nano. 2020;14(5):5179–5182.